# US 2010/0144896 A1 · Thixotropic pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144896 A1
- Document ID: US20100144896A1
- Status: Published application
- Kind: A1
- Application number: 12/527,120
- Filed: 2008-02-04
- Published: 2010-06-10
- Earliest claimed: 2007-02-15
- Inventors: Mikyoung Hahn; Se-Hyun Song; Hee-Jeong Lim; Jin-Woo Choi; Hyeon Kuk
- Web page: https://patentgrep.com/patent/US20100144896A1

## CPC

- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a thixotropic pharmaceutical composition in which the viscosity is changed due to external mechanical stress applied so that isothermal and continuous gel/sol/gel transition occurs. The thixotropic pharmaceutical composition includes a pharmacologically active substance, a biocompatible thickener having a predetermined thixotropic property, and optionally a hydrophilic thickener. The viscosity of the composition is relatively rapidly changed within a predetermined range. Accordingly, it is easy to measure the amount of drugs to be administered, it is possible to administer a precise amount of drugs to a patient, the compliance of a patient with dosage of drugs is high, and it is easy to produce the composition.

## Claims

### Claim 1

A thixotropic pharmaceutical composition that is a drug delivery composition comprising:
at least one pharmacologically active substance;
a liquid substrate; and
at least one biocompatible thickener having a thixotropic property,
and having an equilibrium viscosity of 4,000 cps or less.

### Claim 2 (depends on 1)

The thixotropic pharmaceutical composition according to claim 1, wherein a difference between an initial viscosity and the equilibrium viscosity is at least 3,000 cps or more.

### Claim 3 (depends on 1)

The thixotropic pharmaceutical composition according to claim 1, wherein a time taken up by transition from the equilibrium viscosity to the initial viscosity is in the range of 10 sec to 30 sec.

### Claim 4 (depends on 1)

The thixotropic pharmaceutical composition according to claim 1, wherein the biocompatible thickener is included in an amount ranging from 0.01% (w/v) to 12% (w/v).

### Claim 5 (depends on 4)

The thixotropic pharmaceutical composition according to claim 4, wherein the biocompatible thickener is included in an amount ranging from 0.01% (w/v) to 5% (w/v).

### Claim 6 (depends on 1)

The thixotropic pharmaceutical composition according to claim 1, wherein the biocompatible thickener is one or more selected from the group consisting of an agar, a carrageenan, a gellan gum, colloidal silicon dioxide, and a xanthan gum.

### Claim 7 (depends on 1)

The thixotropic pharmaceutical composition according to claim 1, further comprising one or more selected from the group consisting of a sweetener and a flavor.

### Claim 8 (depends on 7)

The thixotropic pharmaceutical composition according to claim 7, wherein the sweetener is one or more selected from the group consisting of sugar alcohols including mannitol, maltitol, sorbitol, xylitol, and isomalt that do not cause a tooth decay, aspartames, acesulfames, saccharins, calcium saccharin, sodium saccharin, and sucraloses.

### Claim 9 (depends on 1)

The thixotropic pharmaceutical composition according to claim 1, further comprising organic acids.

### Claim 10 (depends on 9)

The thixotropic pharmaceutical composition according to claim 9, wherein the organic acids are one or more selected from the group consisting of a citric acid, an ascorbic acid, a palmitic acid, and a tartaric acid.

### Claim 11 (depends on 1)

The thixotropic pharmaceutical composition according to claim 1, further comprising a hydrophilic thickener.
